Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS | O94925 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.40 |
| ▸ | IDH1 | O75874 | 2/20 | 0.39 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42111 | 1.00 | GLS (0.49) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL9036084 | 1.00 | GLS (0.49) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL42224 | 0.88 | GLS (0.51) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL43071 | 0.88 | GLS (0.51) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL1285658 | 0.88 | GLS (0.51) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL28464253 | 0.87 | NPC1 (0.46) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL15743835 | 0.85 | GLS (0.49) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL15743848 | 0.85 | GLS (0.49) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL14665118 | 0.82 | GLS (0.49) | GLSNPC1LMNATP53HPGD | |
| SCHEMBL14665137 | 0.82 | GLS (0.49) | GLSNPC1LMNATP53HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295373-B | Compositions and methods for treating brain injury | 阿泽凡药物公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| CN-116327950-A | Use of a composition for the treatment of neuropsychiatric symptoms of neurodegenerative diseases | 阿泽范药品公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116139282-A | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-05-23 | — | — | CN | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-106459021-B | Compositions and methods for treating neurodegenerative diseases | 阿泽范药品公司 | 2023-04-07 | — | — | CN | disclosed |
| EP-3122743-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| EP-0301877-A1 | A method of deprotection of 3-amino azetidinones | ELI LILLY AND COMPANY (US) | 1989-02-01 | — | — | EP | disclosed |
| US-4791106-A | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1988-12-13 | — | — | US | disclosed |
| US-4778884-A | REACTING TRIFLUOROMETHYLSULFONYLOXY COMPOUND WITH LITHIUM HALIDE IN APROTIC POLAR SOLVENT | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 1988-10-18 | — | — | US | disclosed |
| US-4775752-A | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-10-04 | — | — | US | disclosed |
| US-4734495-A | Process and intermediates for beta-lactam antibiotics | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1988-03-29 | — | — | US | disclosed |
| EP-0232623-A1 | 1-Carbacephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1987-08-19 | — | — | EP | disclosed |
| US-4673737-A | ANTIBIOTICS/ | HARVARD UNIVERSITY (US) | 1987-06-16 | — | — | US | disclosed |
| US-4665171-A | CARBACEPHALOSPORINS | HARVARD UNIVERSITY (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0211540-A1 | Intermediates and process for antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-02-25 | — | — | EP | disclosed |
| EP-0209352-A2 | Process and intermediates for beta-lactam antibiotics | THE PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1987-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | GLS 1719/4885NPC1 705/4885LMNA 451/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | GLS 775/4885NPC1 253/4885LMNA 1342/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | GLS 775/4885NPC1 253/4885LMNA 1342/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | GLS 1719/4885NPC1 705/4885LMNA 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.